Lateral Epicondylitis Treatment Market - By Treatment Type, By Age Group, By End Use - Global Forecast 2025 – 2034

Lateral Epicondylitis Treatment Market Size

The global lateral epicondylitis treatment market was estimated at USD 1.6 billion in 2024. The market is expected to grow from USD 1.7 billion in 2025 to USD 2.5 billion in 2034, at a CAGR of 4.2%. The major factors that contribute to the growth of the market include the increasing prevalence of lateral epicondylitis owing to increasing participation in sports activities and surge in technological advancement in treatment methodologies.
 

In addition, lateral epicondylitis commonly affects individuals aged between 35 and 60, particularly those engaged in repetitive arm and wrist activities. For example, as per the report published by Boston Children’s Hospital, 1-3% of the general population is affected by tennis elbow annually, with athletes making up a significant portion of these cases. Therefore, the rising sports and recreational activities increases the risk of tennis elbow injury thereby boosting the growth of the market.
 

Furthermore, the market is bolstered by the growing geriatric population coupled with advancement in treatment options such as biological therapies (platelet rich plasm (PRP), stem cell therapy) and rising demand for minimally invasive surgical techniques. For example, as per the World Health Organization report, it is estimated that by 2050, the population aged 60 and older is projected to reach 2.1 billion. Therefore, the increasing global geriatric population increases the risk of musculoskeletal conditions, such as tennis elbow and various others, which increases the demand for novel orthopedic treatments, thereby driving market growth. Additionally, the growing preference for non-invasive therapies due to patients increasingly choosing non-surgical options such as physiotherapy, corticosteroid injections, and shockwave therapy to lower risks and quicker recovery, contributing to the market growth.
 

Moreover, the increase in the number of sports activities conducted annually at global and regional levels raises the number of individuals participating in sports-related activities such as racket sports, weightlifting, and baseball. This has led to an increase in risk of lateral epicondylitis, which augments the market growth. For example, as per the report published by Sports Destination Management, it has been reported that a total of 242 million people in the U.S., nearly 80% of all Americans 6 years and older, participated in at least one sports or fitness activity in 2023, which is a 2.2% increase from 2022, making it the highest number of people that have ever participated in an activity in one year. Therefore, the involvement of more individuals in sport and physical activities increases the risk for occupational injuries, thereby contributing to market growth.
 

Tennis elbow, also known as lateral epicondylitis, is a condition that can result from overuse of the muscles and tendons in the elbow. Tennis elbow is often linked to repeated motions of the wrist and arm. The lateral epicondylitis treatment market refers to the global industry focused on providing medical solutions for lateral epicondylitis.  The market includes products, therapies, and services aimed at managing and alleviating symptoms of lateral epicondylitis.
 

Lateral Epicondylitis Treatment Market Trends

• The growing interest in regenerative medicine, such as stem cell therapies and platelet-rich plasma (PRP), has significantly impacted the treatment market. These therapies offer alternatives for patients who do not respond well to traditional treatments.
   
• The development of advanced therapeutic devices, such as extracorporeal shock wave therapy (ESWT), ultrasound-guided injections, and wearable devices for rehabilitation, has enhanced treatment outcomes and reduced recovery times, which is anticipated to boost market growth.
   
• For instance, PRP therapy has seen rise in popularity, with studies showing up to 70% improvement in symptoms among patients who have received PRP treatment compared to conventional treatments. Therefore, the advancement in technology and introduction of new therapies for treatment has significantly contributed to the growth of the lateral epicondylitis treatment market.
   
• Additionally, the easy availability of over-the-counter drugs such as NSAIDs, corticosteroid injections, and other supportive treatments for lateral epicondylitis drives market growth.
   
• Moreover, the increasing initiatives by government and private organizations to raise awareness about treatment options and availability of non-invasive treatment encourage more patients to seek treatment for lateral epicondylitis, thereby contributing to market growth. For example, the American Academy of Orthopaedic Surgeons introduced an awareness program on “Therapeutic Exercise Program for Epicondylitis” to promote muscle endurance and improve resistance to repetitive stress that leads to lateral epicondylitis.
   
• Lastly, the increasing demand for regenerative therapies with increasing investment in clinical trials by key players in the market for the development of regenerative medicines-based innovative therapies such as stem cell therapy and growth factor injections drives the market growth during the analysis period.
   

Lateral Epicondylitis Treatment Market Analysis

Based on treatment type, the global market is divided into non-surgical treatment and surgical treatment. The non-surgical treatment segment dominated the market and was valued at USD 1.4 billion in 2024. The market size of non-surgical treatment segment was USD 1.28 billion in 2021, and USD 1.32 billion and USD 1.36 billion in 2022 and 2023, respectively.
 

• The increasing preference for non-surgical treatments such as physical therapy, medications, braces, and extracorporeal shock wave therapy has demonstrated significant effectiveness in alleviating pain and promoting healing in lateral epicondylitis cases, that further contribute to market growth. For example, as per the report published by ISAPS, surgical and non-surgical procedures showed significant increases in the last few years (16.7% and 7.2% respectively) with a significant increase of 57.8% in non-surgical procedures in the last four years.
   
• Additionally, recent developments in non-surgical procedures such as platelet rich plasma injection, autologous body products, and botulinum toxins shows positive results in pain relief and functional improvement, thereby boosting market growth. For example, as per the report published in the American Journal of Sports Medicine, it has been reported that PRP therapy showed 70% improvement in pain within 6 months compared to corticosteroids injections.
   
• Moreover, non-surgical treatments are more affordable and accessible compared to surgical options. The lower cost and reduced need for specialized surgical facilities make these treatments more widely available, particularly in regions with limited healthcare resources, contributing to their increased adoption.

Based on the age group, the global lateral epicondylitis treatment market is categorized into pediatric, adult, and geriatric. The adult segment accounted for the highest market share of 71.4% in 2024.
 

• Adults who work in occupations or recreational activities that involve repetitive motions of the forearm and elbow are at a higher risk of developing lateral epicondylitis. The repetitive use of the wrist against resistance can lead to tendon weakening and pain, driving the demand for effective treatments. As per the studies conducted, it has been observed that lateral epicondylitis affected individuals aged 40 to 49, with an incidence rate of 7.8 per 1,000 men and 10.2 per 1,000 women.
   
• Moreover, there is a growing number of sports events and competitions, especially in regions such as North America, leading to a higher incidence of sports-related injuries, including lateral epicondylitis. This trend contributes to the expansion of the treatment market as more individuals seek medical attention for such conditions. For example, as per the report published by John Hopkins Medicine, about 30 million children and teens participate in some form of organized sports, and more than 3.5 million injuries each year in the U.S. Almost one-third of all injuries incurred in childhood are sports-related injuries.
   
• Furthermore, increased awareness about musculoskeletal disorders and improved diagnostic techniques have led to earlier detection and treatment of lateral epicondylitis among adults. Early intervention can prevent the progression of the condition, thereby increasing the demand for treatment options, that spur market growth.
   

Based on the end use, the global lateral epicondylitis treatment market is categorized into hospitals, ambulatory surgical centers, orthopedic clinics, homecare settings, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 924.1 million by 2034.
 

• The growing prevalence of lateral epicondylitis, especially in populations engaged in repetitive motions, contributes to higher patient volumes requiring medical intervention in hospital settings, contributing the market growth.
   
• Additionally, hospitals provide advanced diagnostic tools such as MRI, ultrasound and therapies such as corticosteroid, PRP (Platelet-Rich Plasma) therapy, and surgery, which are less commonly available at outpatient clinics.
   
• Moreover, rising healthcare spending globally, particularly in developed countries, supports the expansion of hospital infrastructure, enabling more treatments and procedures related to lateral epicondylitis. For example, according to the World Health Organization (WHO), global health expenditure is expected to increase at an annual rate of 4.3% over the next decade, benefiting hospital growth and patient treatment access.
   
• In addition, many hospitals offer integrated rehabilitation healthcare services that include physiotherapy, occupational therapy, shockwave therapy, and others that lead to improving patient outcomes for lateral epicondylitis, thereby contributing to market growth.
   
• Thus, the increased patient volume, advanced treatment options, rising healthcare spending, and enhanced awareness of sports medicine, supported by insurance reimbursements and government support for musculoskeletal care, drives the market growth.

The North America lateral epicondylitis treatment market dominated the global market with market share of 43.9% in 2024. In 2024, the U.S. held a significant position in the North America market and was valued at USD 656 million.
 

• The increased participation in sports, physical activities, and manual labor jobs is contributing to higher rates of lateral epicondylitis. For example, according to a report by the National Sporting Goods Association (NSGA), about 19.6 million people in the U.S. play tennis, which correlates with a higher incidence of tennis elbow, that further contributes to the market growth.
   
• Moreover, the availability of effective pain management options, including corticosteroid injections, hyaluronic acid injections, and topical analgesics, also contributes to the growth of the treatment market.
   

Furthermore, the growing number of sports medicine clinics and rehabilitation centers in the U.S. is improving access to specialized care for lateral epicondylitis. These centers offer targeted treatments such as physical therapy and shockwave therapy, increasing patient compliance and treatment outcomes.
 

Germany lateral epicondylitis treatment market shows strong growth potential in the Europe market.
 

• The increasing awareness among the German population about non-surgical treatment options for lateral epicondylitis, such as physical therapy, corticosteroid injections, platelet-rich plasma (PRP) therapy, and shockwave therapy drives the market growth.
   
• Moreover, the greater number of people doing desk jobs and living sedentary lifestyles in Germany, are increasingly experiencing repetitive strain injuries. In addition, the country's strong industrial and manufacturing sectors contribute to work-related musculoskeletal disorders, leading to higher demand for treatment options.
   
• In addition, Germany has one of the largest aging populations in Europe. As people age, the risk of musculoskeletal disorders, including lateral epicondylitis, increases. This contributes to the demand for treatments aimed at managing age-related injuries such as tennis elbow further contributing to market growth. For example, Statistisches Bundesamt report stated that, 4 million more people aged 67 or over will live in Germany in 2035.
   
• Additionally, the increasing adoption of regenerative medicine in Germany with increasing demand for minimally invasive treatment for lateral epicondylitis drives the growth of the market. For example, Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM) recently approved a new biological formulation for tendinopathy treatment. Therefore, the increasing usage of biological therapies such as platelet rich plasma injections, stem cell therapy, and shockwave therapy contributed to market growth.
   

The lateral epicondylitis treatment market in Asia Pacific is estimated to grow at a CAGR of 4.5% over the next few years.
 

• China's healthcare system is undergoing rapid improvements, particularly in urban areas, which leads to more patients being diagnosed and treated for lateral epicondylitis.
   
• Moreover, China's aging demographic contributes to an increased prevalence of musculoskeletal disorders, including lateral epicondylitis. As individuals age, tendon elasticity decreases, making them more susceptible to injuries such as tennis elbow. This demographic shift is driving demand for effective treatment options.
   
• Additionally, China's investment in healthcare infrastructure and increased healthcare spending have enhanced the availability and quality of medical services. This improvement facilitates better diagnosis and treatment of conditions such as lateral epicondylitis, contributing to market growth.
   
• In addition, patients in China are increasingly opting for non-surgical treatments due to faster recovery times. For example, a 2023 report published by the Chinese Orthopedic Association, stated that over 60% of lateral epicondylitis cases in urban hospitals are managed using non-surgical interventions.
   

Latin America: Brazil's lateral epicondylitis treatment market is projected to witness growth in coming years.
 

• Brazil's cultural emphasis on sports and physical activities, such as football, volleyball, and tennis, leads to a higher incidence of sports-related injuries, including lateral epicondylitis. This active lifestyle contributes to the demand for effective treatment solutions.
   
• Furthermore, Brazil's large and diverse population contributes to a significant number of individuals affected by musculoskeletal conditions, including lateral epicondylitis. This high prevalence increases the demand for effective treatment options, that contribute to market growth.
   

Saudi Arabia lateral epicondylitis treatment market is anticipated to grow in the Middle East and African market.
 

• Saudi Arabia has been focusing on improving its healthcare infrastructure as part of its Vision 2030 reform plan. This includes expanding the capacity of hospitals and introducing modern healthcare technologies, which has positively impacted the availability and access to treatments for musculoskeletal injuries such as lateral epicondylitis.
   
• Moreover, with a growing number of office workers and manual laborers, there has been a noticeable rise in overuse injuries, including lateral epicondylitis. Long hours spent on computers or performing repetitive manual tasks can lead to strain on the elbow tendons, contributing to the rising number of tennis elbow cases.
   
• Additionally, the expansion of private healthcare players such as Saudi German Hospital, Fakeeh hospital, and others has improved access to specialized orthopedic treatments making treatment more accessible, thereby contributing to market growth.
   

Lateral Epicondylitis Treatment Market Share

The top 6 players such as Pfizer, DJO Global (Enovis), Zimmer Biomet, 3M Company, Novartis, and Ossur Corporate accounts for approximately 60%-65% of the market share in 2024. These players focus on various strategies such as acquisition, business expansion, research and development activities and novel product launches to consolidate their market presence. For instance, in December 2024, Zimmer Biomet Holdings, a global medical technology leader, announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit stemless shoulder system for total shoulder replacement. Established pharmaceutical giants offer a well-known lateral epicondylitis treatment products under various brand names.
 

Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. Companies are actively adopting multi-pronged approaches to address the rising demand for lateral epicondylitis treatment. Furthermore, the market is highly consolidated with few players operating in the market. Hence, leading players are constantly adopting key strategies for the growth of the market. Companies are focusing on product differentiation, regulatory approvals, and strategic partnerships to strengthen their position in this competitive market.
 

Lateral Epicondylitis Treatment Market Companies

Few of the prominent players operating in the lateral epicondylitis treatment industry include:

• 3M Company
• BTL
• DJO Global (Enovis)
• Folsom Orthopaedics & Sports Medicine
• GlaxoSmithKline
• MedStar Health
• Merck & Co
• Novartis
• Ossur Corporate
• Pfizer
• Pharmascience
• ReLiva Physiotherapy & Rehab
• Scandinavian Physiotherapy Center
• Zimmer Biomet 
   

Pain Care Labs is engaged in the development of treatment options for lateral epicondylitis. The company aims to develop novel therapeutics for the treatment of tennis elbow. In May 2023, repetitive stress on the forearm tendons may respond to bracing or surgery, the pain remains. The FDA has cleared VibraCool, a first-in-class novel ice and vibration wearable, to treat the pain from muscle tension and restriction in Tennis Elbow (tendinitis). Additionally, tennis elbow affects millions of people worldwide with pain and inflammation. VibraCool combines unique flat freeze-solid ice packs and a high-frequency vibration unit to reduce pain in a soft compression cuff.
 

The company focuses on addressing customer needs and tackling key business challenges. The company’s health platform integrates with minimally invasive techniques, and introduction of shockwave therapy (ESWT) and ultrasound-guided corticosteroid injections to offer efficacy in disease management.
 

Lateral Epicondylitis Treatment Industry News

• In March 2023, Regenexx, a leader in regenerative medicine, announced the launch of a new line of orthobiologics, which includes advanced Platelet-Rich Plasma (PRP) treatments specifically designed to treat musculoskeletal conditions such as lateral epicondylitis. These PRP therapies aim to promote healing and reduce inflammation for patients suffering from tennis elbow, offering a non-invasive alternative to surgery.
   
• In February 2023, ZetrOZ Systems offers the sam sport pain relief device, a wearable, drug-free, noninvasive alternative to medication and surgery. This helped the company expand its product range.
   
• In March 2022, NanoVibronix announced plans to expand its product line with the introduction of PainShield RELIEF, an over-the-counter ultrasound therapy device designed to provide rapid pain relief for nerve and soft tissue damage. This device aims to make pain relief more accessible by eliminating the need for a clinician's prescription.
   

The lateral epicondylitis treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Non-surgical treatment
  • Medications
  • Physical therapy
  • Orthotics and braces
  • Other non-surgical treatments
• Surgical treatment
  • Arthroscopic surgery
  • Open surgery
  • Other surgical treatments

Market, By Age Group

• Pediatric
• Adult
• Geriatric

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Orthopedic clinics
• Homecare settings
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE